<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466866</url>
  </required_header>
  <id_info>
    <org_study_id>R01DK114033-01A1</org_study_id>
    <nct_id>NCT03466866</nct_id>
  </id_info>
  <brief_title>Reducing Emergency Diabetes Care for Older African Americans</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>Randomized Controlled Trial of Preventing and Reducing Emergency Visits in Diabetes Through Education and Telehealth vs. Diabetes Education to Reduce Emergency Visits and Hospitalizations Over 12 Months in African Americans Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This RCT will compare the efficacy of Preventing and Reducing Emergency Visits in Diabetes&#xD;
      through Education and Trust (PREVENT) vs. intensive home-based diabetes (DM) education [i.e.,&#xD;
      Enhanced Usual Care (EUC)] to reduce DM-related emergency department (ED) visits and/or&#xD;
      hospitalizations over 12 months (primary outcome) in 230 blacks with diabetes, 50 years and&#xD;
      older, after an ED visit. A moderation analysis will determine whether participants who&#xD;
      reside in low- vs. high-need communities [defined by Community Need Index scores (i.e., an&#xD;
      indicator of the built environment)] respond differently to treatment.&#xD;
&#xD;
      PREVENT is a collaborative intervention of Primary Care Physicians, (PCPs), a DM nurse&#xD;
      educator, and Community Health Workers (CHWs) that extends from the ED into the community.&#xD;
      The CHWs will: 1) deliver in-home DM education to increase participants' knowledge and skills&#xD;
      to manage DM; 2) use DM-specific Behavioral Activation to reinforce DM self-care; and 3)&#xD;
      facilitate telehealth visits with PCPs and a DM nurse educator to increase access to care.&#xD;
      The control treatment, EUC, is home-based intensive DM education. EUC matches PREVENT in&#xD;
      treatment intensity (i.e., number and duration of in-home visits) and delivery of DM&#xD;
      self-care education, but does not include PREVENTS's other active elements (i.e., Behavioral&#xD;
      Activation and telehealth). The treatment comparison will identify PREVENTS's specific&#xD;
      efficacy over and above EUC. We hypothesize that PREVENT will halve the rate of incident&#xD;
      DM-related ED visits and/or hospitalizations relative to EUC. The three secondary outcomes&#xD;
      are: 1) subjective perceptions of access to care; 2) receipt of DM Quality Metrics (i.e.,&#xD;
      objective indicators of realized access to care); and 3) DM self-care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase-III RCT will compare the efficacy of Preventing and Reducing Emergency Visits in&#xD;
      Diabetes through Education and Trust (PREVENT) vs. intensive home-based DM education to&#xD;
      reduce the number of DM-related ED visits and/or hospitalizations over 12 months (primary&#xD;
      outcome), in 230 AAs with DM, 40 years and older, who are recruited from the ED after an ED&#xD;
      visit. PREVENT is a culturally relevant intervention that extends from the ED to the&#xD;
      community, and aims to improve access to care and DM self-care (secondary outcomes). A&#xD;
      mediation analysis will determine whether changes in access to care and/or DM self-care&#xD;
      explain PREVENT's efficacy. A moderation analysis will determine whether participants who&#xD;
      reside in low- vs. high-need communities [defined by Community Need Index scores (i.e., an&#xD;
      indicator of the built environment)] respond differently to treatment.&#xD;
&#xD;
      PREVENT will begin soon after the participant's index ED visit, when many patients remain&#xD;
      uncertain how to manage DM or how to access follow-up care. Community Health Workers (CHWs),&#xD;
      who are race-concordant with participants, will: 1) deliver in-home DM education to increase&#xD;
      participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM&#xD;
      self-care; and 3) facilitate telehealth visits with the participant's primary care physician&#xD;
      (PCP) and a DM nurse educator to increase access to care. The control treatment, EUC, is&#xD;
      intensive home-based DM education. EUC matches PREVENT in treatment intensity (i.e., 6&#xD;
      in-home sessions over 4 months, and 3 booster sessions over the next 8 months) and delivery&#xD;
      of culturally relevant DM education, but does not include DM-specific Behavioral Activation&#xD;
      or telehealth visits. The treatment comparison will identify PREVENT's specific efficacy over&#xD;
      and above EUC.&#xD;
&#xD;
      This RCT is significant as the population ages and becomes more racially diverse, and as ED&#xD;
      use and costs increase. This RCT is innovative because it: 1) tests the first ED-to-community&#xD;
      intervention designed to reduce the need for ED care in AAs with DM; 2) assesses both&#xD;
      subjective and objective indicators of access to care; and 3) defines the specific&#xD;
      characteristics of COPDE that confer its cultural relevance. If successful, PREVENT will meet&#xD;
      Healthy People 2020's twin goals of reducing the personal and societal costs of DM and&#xD;
      achieving health equity for all Americans. The Specific Aims of this RCT are:&#xD;
&#xD;
      Primary Specific Aim: Test the efficacy of PREVENT to reduce the number of incident&#xD;
      DM-related ED visits and/or hospitalizations over 12 months (primary outcome) in AAs with DM.&#xD;
      Hypothesis: PREVENT will halve the number of incident DM-related ED visits and/or&#xD;
      hospitalizations relative to EUC over 12 months.&#xD;
&#xD;
      The Secondary Aims are to:&#xD;
&#xD;
        1. Test the efficacy of PREVENT to increase perceived access to care over 12 months&#xD;
           (secondary outcome). Hypothesis: PREVENT will increase Patient Satisfaction&#xD;
           Questionnaire-18 scores to a greater extent than EUC over 12 months.&#xD;
&#xD;
        2. Test the efficacy of PREVENT to increase realized access to care over 12 months&#xD;
           (secondary outcome). Hypothesis: PREVENT will increase the number of received Diabetes&#xD;
           Quality Metrics (e.g., hemoglobin A1c testing, urine screening) to a greater extent than&#xD;
           EUC over 12 months.&#xD;
&#xD;
        3. Test the efficacy of PREVENT to improve DM self-care over 12 months (secondary outcome).&#xD;
           Hypothesis: PREVENT will increase Diabetes Self-Care Inventory scores to a greater&#xD;
           extent than EUC over 12 months.&#xD;
&#xD;
        4. Determine if increasing subjective and/or objective indicators of access to care and/or&#xD;
           DM self-care mediates PREVENT's reduction of DM-related ED visits and/or&#xD;
           hospitalizations. Hypothesis: PREVENT will reduce DM-related ED visits and/or&#xD;
           hospitalizations to the extent that it increases subjective and/or objective indicators&#xD;
           of access to care and/or improves DM self-care.&#xD;
&#xD;
      The Exploratory Aims are to: 1) determine whether PREVENT reduces &quot;all cause&quot; ED&#xD;
      visits/hospitalizations relative to EUC.; 2) determine whether Community Need Index scores,&#xD;
      literacy, age, and/or sex moderate treatment effects; 3) determine if PREVENT improves&#xD;
      glycemic control (i.e., lowers hemoglobin A1c levels), impacts DM-related health beliefs,&#xD;
      reduces depression, and/or improves quality-of-life; 4) identify PREVENT's treatment features&#xD;
      that confer its cultural relevance; and 5) estimate PREVENT's costs and net financial benefit&#xD;
      to the healthcare system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single blind, randomized controlled trial</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of incident diabetes-related ED visits and/or hospitalizations</measure>
    <time_frame>12 months</time_frame>
    <description>The primary efficacy analysis will consider the number of incident diabetes-related ED visits and/or hospitalizations (i.e., an &quot;event&quot;) over 12 months after the index ED visit. Each ED visit or hospitalization is counted as a single event (although an ED visit that leads to a hospitalization is counted once). ED visits and hospitalization will be ascertained through chart reviews and subject self-report.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived access to health care</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Patient Satisfaction Questionnaire-18 scores from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual access to care</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in the number of received Diabetes Quality Metrics (e.g., hemoglobin A1c testing, urine screening) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes self-care behaviors</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of engagement in diabetes self-care behaviors (e.g., exercise, diet) as measured by the Diabetes Self-Care Inventory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>COPDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Diabetes Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In-home diabetes education</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>COPDE</intervention_name>
    <description>Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.</description>
    <arm_group_label>COPDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive Diabetes Education</intervention_name>
    <description>In-home diabetes education</description>
    <arm_group_label>Intensive Diabetes Education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. African American race (self-identified)&#xD;
&#xD;
          2. Age â‰¥ 50 years&#xD;
&#xD;
          3. Type 1 or 2 DM&#xD;
&#xD;
          4. A DM-related cause for the ED visit in the opinion of the ED physician&#xD;
&#xD;
          5. Has a Jefferson PCP (participants receiving COPDE will have a telehealth visit with&#xD;
             their Jefferson PCP).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical or psychiatric morbidity (e.g., acute stroke, schizophrenia) that would&#xD;
             preclude study participation in the opinion of the ED physician&#xD;
&#xD;
          2. Clinically significant cognitive impairment&#xD;
&#xD;
          3. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry w Rovner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin J Casten, PhD</last_name>
      <phone>215-503-1250</phone>
      <email>Robin.Casten@Jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Barry Rovner</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

